Bevacizumab (anti-VEGF)

Catalog No.A2006 Batch: A200603

Technical Data

CAS No.	216974-75-3
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	CHO cells
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity	99.3%
Protein concentration	5mg/ml
Endotoxin Level	≤1 EU/mg

Biological Activity

Description

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Targets

VEGFR2 ^[4]

VEGF-A ^[4]

VEGF ^[1]

In vitro

Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.^[1]

In vivo

The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.^[2]

Protocol (Only for Reference)

Cell Assay:	Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.
Animal Study:	Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model Dosages: 2 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/

Cell Assay:

Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

Animal Study:

Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model
Dosages: 2 mg/kg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/

References	[1] Hurley-Novatny AC, et al. J Invest Dermatol. 2022 Feb 19:S0022-202X(22)00125-7. [2] Lin Y, et al. Hepatology. 2021 Dec 23.

References

Customer Product Validation

Data from [Data independently produced by , , Cancer Lett, 2018, 439:78-90]

VEGFA expression in the indicated cells treated with or without bevacizumab or transfected with VEGFA or shVEGFA.

Selleck's Bevacizumab (anti-VEGF) has been cited by 47 publications

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth [ Nat Commun, 2024, 15(1):1359]	PubMed: 38355578
Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins [ Front Immunol, 2024, 15:1273280]	PubMed: 38533506
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway [ Front Oncol, 2024, 14:1302850]	PubMed: 38420012
Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis [ ESC Heart Fail, 2024, 11(2):986-1000]	PubMed: 38234115
Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis [ ESC Heart Fail, 2024, 10.1002/ehf2.14640]	PubMed: 38234115
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade [ Cancer Immunol Res, 2023, 11(11):1493-1507]	PubMed: 37728484
L1CAM promotes vasculogenic mimicry formation by miR-143-3p-induced expression of hexokinase 2 in glioma [ Mol Oncol, 2023, none]	PubMed: 36708044
Vascularized Immunocompetent Patient-Derived Tumor Model to Predict Treatment Response for Lung Cancer Patients [ iScience, 2023, Volume 26, Issue 10]	PubMed: none
In vitro vascularized immunocompetent patient-derived model to test cancer therapies [ iScience, 2023, 26(10):108094]	PubMed: 37860774
In vitro vascularized immunocompetent patient-derived model to test cancer therapies [ iScience, 2023, 26(10):108094]	PubMed: 37860774

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.